sample size calculation vaccines – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Sat, 02 Aug 2025 19:34:17 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 Bridging Studies Between Age Groups in Vaccines https://www.clinicalstudies.in/bridging-studies-between-age-groups-in-vaccines/ Sat, 02 Aug 2025 19:34:17 +0000 https://www.clinicalstudies.in/bridging-studies-between-age-groups-in-vaccines/ Read More “Bridging Studies Between Age Groups in Vaccines” »

]]> Bridging Studies Between Age Groups in Vaccines

Designing Age-Group Immunobridging Studies for Vaccines

What Immunobridging Aims to Show—and When Regulators Expect It

Age-group immunobridging studies answer a practical question: if a vaccine’s dose and schedule are proven in one population (often adults), can we infer comparable protection in another (adolescents, children, older adults) without running a full-scale efficacy trial? The bridge rests on immune endpoints that are reasonably likely to predict clinical benefit—typically ELISA IgG geometric mean titers (GMTs), neutralizing antibody titers (ID50 or ID80), and sometimes cellular readouts (IFN-γ ELISpot). The usual primary analysis is non-inferiority (NI) of the younger (or older) age cohort versus the reference adult cohort using a GMT ratio framework and/or seroconversion difference. Safety and reactogenicity must also be comparable and acceptable for the target age group, with age-appropriate grading scales and follow-up windows.

Regulators expect immunobridging when disease incidence is low, when placebo-controlled efficacy is impractical or unethical, or when efficacy has already been established in adults. Pediatric development triggers added ethical considerations—parental consent, child assent, minimization of painful procedures—and may start with older strata (e.g., 12–17 years) before de-escalating to younger cohorts. Your protocol should anchor objectives to a clear estimand: for example, “treatment policy” estimand for immunogenicity regardless of post-randomization rescue vaccination, with pre-specified handling of intercurrent events. For practical regulatory context, see high-level principles in FDA vaccine guidance and adapt them to your product-specific advice meetings. For operational SOP templates aligning protocol, SAP, and monitoring plans, a helpful starting point is PharmaSOP.

Endpoints, Assays, and Fit-for-Purpose Validation Across Ages

Bridging succeeds or fails on the reliability of its immunogenicity endpoints. A common designates two coprimary endpoints: (1) GMT ratio NI (younger/adult) with a lower bound NI margin (e.g., 0.67) and (2) seroconversion rate (SCR) difference NI with a lower bound margin (e.g., −10%). Endpoints are typically assessed at a post-vaccination timepoint (e.g., Day 28 or Day 35 after the last dose). Assays must be consistent across cohorts—same platform, reference standards, and cut-points—because analytical variability can masquerade as biological difference. Declare LLOQ, ULOQ, and LOD in the lab manual and SAP and specify data handling rules (e.g., below-LLOQ values imputed as LLOQ/2).

Illustrative Assay Parameters and Decision Rules
Assay LLOQ ULOQ LOD Precision (CV%) Responder Definition
ELISA IgG 0.50 IU/mL 200 IU/mL 0.20 IU/mL ≤15% ≥4-fold rise from baseline
Neutralization (ID50) 1:10 1:5120 1:8 ≤20% ID50 ≥1:40
ELISpot IFN-γ 10 spots 800 spots 5 spots ≤20% ≥3× baseline & ≥50 spots

Where lot changes occur between adult and pediatric studies, coordinate with CMC to document comparability. Although clinical teams do not compute manufacturing PDE or cleaning MACO limits, referencing example PDE (e.g., 3 mg/day) and MACO swab limits (e.g., 1.0 µg/25 cm2) in the dossier reassures ethics committees that supplies meet safety expectations. Finally, confirm sample processing equivalence (same centrifugation, storage at −80 °C, allowable freeze–thaw cycles) to avoid artefacts that could distort between-age comparisons.

Designing the Bridge: Cohorts, NI Margins, Power, and Multiplicity

Typical bridging compares an age cohort (e.g., 12–17 years) against a concurrently or historically enrolled adult cohort receiving the same dose/schedule. Randomization within the pediatric cohort (e.g., vaccine vs control or schedule variants) may be used to assess tolerability and alternate dosing, but the immunobridging comparison is vaccine vs adult vaccine. NI margins should be justified by assay precision, prior platform data, and clinical judgment (e.g., a GMT ratio NI margin of 0.67 and an SCR NI margin of −10% are commonly defensible). Powering depends on assumed GMT variability (SD of log10 titers ≈0.5) and expected SCRs; allow for 10% attrition and multiplicity if testing two coprimary endpoints or multiple age strata.

Illustrative NI Framework and Sample Size (Dummy)
Endpoint NI Margin Assumptions Power N (Pediatric)
GMT Ratio (Ped/Adult) 0.67 (lower 95% CI) SD(log10)=0.50; true ratio=0.95 90% 200
SCR Difference (Ped−Adult) ≥−10% Adult 90% vs Ped 90% 85% 220

Plan age de-escalation (e.g., 12–17 → 5–11 → 2–4 → 6–23 months) with sentinel dosing and Safety Review Committee checks at each step. Define visit windows (e.g., Day 28 ± 2) and intercurrent event handling (receipt of non-study vaccine). Pre-specify multiplicity control (e.g., gatekeeping: GMT NI first, then SCR NI) to maintain Type I error. Establish a DSMB charter with pediatric-appropriate stopping rules (e.g., any anaphylaxis; ≥5% Grade 3 systemic AEs within 72 h) and ensure 24/7 PI coverage and pediatric emergency preparedness at sites.

Executing the Bridge: Recruitment, Ethics, Safety, and Data Quality

Recruitment should mirror the intended pediatric label: balanced sex distribution, representative comorbidities (e.g., well-controlled asthma), and diversity across sites. Informed consent from parents/guardians and age-appropriate assent are mandatory, with materials reviewed by ethics committees. Minimize burden—combine blood draws with visit schedules, use topical anesthetics, and cap total blood volume according to pediatric guidelines. Safety capture includes solicited local/systemic AEs for 7 days post-dose, unsolicited AEs to Day 28, and AESIs (e.g., anaphylaxis, myocarditis, MIS-C-like presentations) throughout. Provide anaphylaxis kits on site, observe for ≥30 minutes post-vaccination (longer for initial subjects), and maintain direct 24/7 contact for guardians.

Data quality hinges on training, calibrated equipment (thermometers for fever grading), validated ePRO diaries, and strict chain-of-custody for specimens (−80 °C storage; ≤2 freeze–thaw cycles). Centralized monitoring uses key risk indicators—out-of-window visits, missing central lab draws, diary non-compliance—to trigger targeted support. The Trial Master File (TMF) must be contemporaneously filed with protocol/SAP versions, monitoring reports, DSMB minutes, and assay validation summaries. For additional regulatory reading on pediatric development principles and quality systems, consult EMA resources. For broader CMC–clinical alignment and case studies, see PharmaGMP.

Case Study (Hypothetical): Bridging Adults to Adolescents and Children

Assume an adult regimen of 30 µg on Day 0/28 with robust efficacy. An adolescent cohort (12–17 years, n=220) and a child cohort (5–11 years, n=300) receive the same schedule. Adult reference immunogenicity at Day 35 shows ELISA IgG GMT 1,800 and neutralization ID50 GMT 320, with SCR 90%. Adolescents return ELISA GMT 1,950 and ID50 GMT 360; children, ELISA 1,600 and ID50 300. Log10 SD≈0.5 in all groups; SCRs: adolescents 93%, children 90%.

Illustrative Immunobridging Results (Day 35, Dummy)
Cohort ELISA GMT ID50 GMT GMT Ratio vs Adult 95% CI SCR (%) ΔSCR vs Adult 95% CI
Adult (Ref.) 1,800 320 — — 90 — —
Adolescent 1,950 360 1.08 0.92–1.26 93 +3% −3 to +9
Child 1,600 300 0.89 0.76–1.05 90 0% −6 to +6

With NI margins of 0.67 for GMT ratio and −10% for SCR difference, both adolescent and child cohorts meet NI for ELISA and neutralization endpoints. Safety is acceptable: Grade 3 systemic AEs within 72 h occur in 2.7% (adolescents) and 2.3% (children), with no anaphylaxis. A pre-specified sensitivity analysis excluding protocol deviations (e.g., out-of-window Day 35 draws) confirms conclusions. The DSMB endorses dose/schedule carry-over to adolescents and children; an exploratory lower-dose (15 µg) arm in younger children is reserved for Phase IV optimization.

Statistics, Sensitivity Analyses, and Multiplicity Control

Primary GMT analyses use ANCOVA on log-transformed titers with baseline antibody level and site as covariates; back-transform to obtain ratios and 95% CIs. SCRs are compared via Miettinen–Nurminen CIs adjusted for stratification factors (age bands). Multiplicity can be handled by gatekeeping: first test adolescent GMT NI, then adolescent SCR NI, then child GMT NI, then child SCR NI—progressing only if the prior test is passed. Sensitivity analyses include per-protocol sets (meeting timing windows), missing-data imputation pre-declared in the SAP (e.g., multiple imputation under missing-at-random), and robustness to alternative cut-points (e.g., ID50 ≥1:80). Pre-specify labs’ analytical ranges to avoid ceiling effects (e.g., ULOQ 200 IU/mL for ELISA, 1:5120 for neutralization), and document how values above ULOQ are handled (e.g., set to ULOQ if not re-assayed).

Documentation, TMF/Audit Readiness, and Next Steps

Before CSR lock, reconcile AEs (MedDRA coding), finalize immunogenicity analyses, and archive assay validation summaries. Update the Investigator’s Brochure with bridging results and pediatric dose/schedule rationale. Ensure controlled SOPs cover pediatric consent/assent, blood volume limits, emergency preparedness, and ePRO management. If manufacturing changes coincided with pediatric lots, include comparability data and reference CMC control limits (PDE and MACO examples) for transparency. For quality and statistical principles relevant to filings, review the ICH Quality Guidelines. With NI demonstrated and safety acceptable, proceed to labeling updates and, if warranted, Phase IV effectiveness or dose-optimization studies in the youngest strata.

]]> Phase II Immunogenicity and Tolerability Studies https://www.clinicalstudies.in/phase-ii-immunogenicity-and-tolerability-studies/ Fri, 01 Aug 2025 10:18:01 +0000 https://www.clinicalstudies.in/phase-ii-immunogenicity-and-tolerability-studies/ Read More “Phase II Immunogenicity and Tolerability Studies” »

]]> Phase II Immunogenicity and Tolerability Studies

Designing Phase II Vaccine Studies for Immunogenicity & Tolerability

What Phase II Vaccine Trials Are Designed to Demonstrate

Phase II vaccine trials expand first-in-human learnings to a larger and more diverse population (often a few hundred participants) with two primary aims: (1) quantify immunogenicity with sufficient precision to compare doses and schedules; and (2) confirm tolerability and safety in a population that better reflects intended use (e.g., broader age ranges, comorbidities controlled). Unlike Phase III, Phase II is not powered for clinical efficacy endpoints; however, it may explore correlates of protection or prespecified thresholds (e.g., neutralizing antibody ID50 ≥1:40) that inform Phase III design. Studies typically randomize participants into 2–4 arms (e.g., two dose levels × one or two schedules) with placebo or active comparator where ethically and scientifically appropriate. Stratification factors (age bands, baseline serostatus) are declared in the Statistical Analysis Plan (SAP) to avoid imbalance.

Operationally, Phase II strengthens safety characterization: solicited local/systemic reactions are captured via ePRO diaries for 7 days post-dose; unsolicited AEs to Day 28; SAEs and AESIs (e.g., anaphylaxis, immune-mediated conditions) throughout. A blinded Safety Review Committee (SRC) or DSMB performs periodic reviews against pre-agreed stopping rules. The output of Phase II is a recommended Phase III dose and schedule (sometimes termed RP3D), supported by a coherent immunogenicity signal and an acceptable reactogenicity profile. Documentation must anticipate audits: protocol and IB version control, TMF filing, monitoring visit reports, and contemporaneous deviation handling all contribute to inspection readiness.

Endpoint Strategy: Immunogenicity Metrics, Assay Validation, and Decision Rules

Immunogenicity endpoints should be clinically interpretable and analytically reliable. Common primary endpoints include geometric mean titer (GMT) of neutralizing antibodies at Day 35 or Day 56, or seroconversion rate (SCR) defined a priori (e.g., ≥4-fold rise from baseline or ID50 ≥1:40 for seronegatives). Secondary endpoints may include ELISA IgG GMTs, responder proportions by cellular assays (IFN-γ ELISpot), and durability at Day 180. Because vaccine decisions hinge on these readouts, fit-for-purpose assay validation is essential—even when assays are exploratory.

Declare key analytical parameters in the SAP and lab manuals: lower/upper limit of quantification (LLOQ/ULOQ), limit of detection (LOD), accuracy, precision, and handling rules for out-of-range values. For example, an ELISA may specify LLOQ 0.50 IU/mL, ULOQ 200 IU/mL, LOD 0.20 IU/mL; a pseudovirus neutralization assay might read out from 1:10 to 1:5120 dilutions, with values <1:10 imputed as 1:5 for analysis. Predefine responder criteria, multiplicity adjustments, and how missing data are handled (e.g., multiple imputation vs. complete case). Although clinical teams don’t compute manufacturing PDE or cleaning MACO limits, referencing that clinical lots meet example PDE (e.g., 3 mg/day) and MACO swab limits (e.g., 1.0 µg/25 cm2) in the CMC section reassures ethics committees about product quality.

Illustrative Immunogenicity Assay Parameters (Define in Lab Manual/SAP)
Assay LLOQ ULOQ LOD Precision (CV%) Responder Definition
ELISA IgG 0.50 IU/mL 200 IU/mL 0.20 IU/mL ≤15% ≥4-fold rise from baseline
Neutralization (ID50) 1:10 1:5120 1:8 ≤20% ID50 ≥1:40
ELISpot IFN-γ 10 spots 800 spots 5 spots ≤20% ≥3× baseline and ≥50 spots

Align endpoint definitions with global expectations to facilitate parallel scientific advice (see FDA resources for vaccines). For a practical framing of protocol language and SOP alignment, review example templates and checklists available via PharmaSOP (internal reference).

Study Design: Arms, Randomization, Power, and Sample Size

Phase II designs commonly compare ≥2 doses and/or schedules (e.g., 10 µg vs 30 µg; Day 0/28 vs Day 0/56). Randomization (1:1:1 or 2:2:1 when including placebo) and blinding reduce bias in reactogenicity reporting and immunogenicity sampling. Power calculations depend on the primary endpoint. For continuous endpoints (log10-transformed GMT), detect a mean difference of 0.2–0.3 with SD≈0.5 using a two-sided α=0.05; for binary endpoints (SCR), detect a 10–15% absolute difference. Account for attrition (5–10%) and stratify by age (e.g., 18–49, ≥50) if those strata will matter in Phase III.

Illustrative Sample Size Scenarios (Two-Arm Comparison)
Endpoint Assumptions Effect to Detect Power N per Arm
GMT (log10) SD=0.50, α=0.05 Δ=0.25 90% 120
Seroconversion Rate plow=70%, α=0.05 +10% (to 80%) 85% 150
Non-inferiority (SCR) Margin=−10% 80% vs 78% 80% 200

Schedule windows (e.g., Day 28 ± 2) balance feasibility and data integrity. Define interim looks (e.g., after 50% randomized) for safety only, maintaining immunogenicity blinding until database lock. If multiple comparisons exist, prespecify a hierarchy or adjust via Hochberg/Bonferroni to protect Type I error. A clear SAP, randomization manual, and monitoring plan ensure decisions are data-driven and auditable.

Tolerability and Safety Monitoring: Reactogenicity, AESIs, and DSMB Conduct

While immunogenicity drives dose/schedule selection, Phase II must demonstrate that the regimen is acceptable to patients. Use standardized, participant-friendly diaries to capture solicited local (pain, erythema, swelling) and systemic events (fever, fatigue, headache, myalgia) for 7 days post-each dose. Grade events using CTCAE definitions and instruct participants on temperature measurement and thresholds (e.g., Grade 3 fever ≥39.0 °C). Unsolicited AEs are collected through Day 28; SAEs and AESIs such as anaphylaxis or immune-mediated events are recorded throughout. The DSMB charter should define meeting cadence (e.g., monthly or by cohort milestones), unblinding rules for safety emergencies, and stopping/pausing criteria.

Illustrative Reactogenicity & Safety Framework
Category Threshold Action
Local Grade 3 ≥10% in any arm DSMB review; consider dose reduction/removal
Systemic Grade 3 ≥5% within 72 h Temporary pause; enhanced monitoring
Anaphylaxis Any related case Immediate hold; unblind case as needed
Liver Enzymes ALT/AST ≥5×ULN >48 h Cohort pause; hepatic panel, causality review

Sites should maintain readiness with anaphylaxis kits, 30-minute post-dose observation (longer for first few subjects per arm), and 24/7 PI coverage. Safety signals must be reconciled with laboratory data (e.g., cytokines) and narratives prepared for notable cases. Transparent, contemporaneous documentation—monitoring visit reports, deviation logs, and DSMB minutes—supports GCP compliance and future inspections.

Case Study: From Phase II Data to a Recommended Phase III Regimen

Imagine a protein-subunit vaccine assessed at 10 µg and 30 µg, each on Day 0/28. In n=300 adults (1:1 randomization), solicited systemic Grade 3 events occurred in 3.0% (10 µg) vs 6.5% (30 µg). ELISA IgG GMTs at Day 35 were 1,200 vs 2,000 (ratio 1.67; 95% CI 1.45–1.92), while neutralization ID50 responder rates (≥1:40) were 86% vs 93% (difference 7%, 95% CI 1–13). Cellular responders (IFN-γ ELISpot) were 62% vs 74%. SAP decision rules predeclared that an increase in SCR of ≥7% with Grade 3 systemic AE difference ≤5% would justify selecting the higher dose; in this dataset, the SCR gain meets the threshold but reactogenicity exceeds the 5% margin. The team therefore conducts a preplanned sensitivity look by age: in ≥50 years, SCR gain is 10% with only a 2% AE increase; in 18–49, gain is 4% with a 6% AE increase. A stratified recommendation emerges: 30 µg for ≥50 years and 10 µg for 18–49, both Day 0/28. This preserves tolerability in younger adults and secures stronger responses in older adults where immunosenescence is expected.

Analytically, the lab confirms ELISA LLOQ 0.50 IU/mL, ULOQ 200 IU/mL, LOD 0.20 IU/mL; values below LLOQ were set to LLOQ/2 for GMT calculations per SAP. For the neutralization assay, titers <1:10 were assigned 1:5. Although not clinical endpoints, the CMC annex to the IB/IMPD documents cleaning MACO limits (e.g., 1.2 µg/swab) and toxicological PDE examples (e.g., 3 mg/day) for residuals, which supports ethics and regulator confidence in product quality.

Documentation, TMF Readiness, and Transition to Phase III

Before locking the Clinical Study Report (CSR), reconcile all safety data (MedDRA coding), finalize immunogenicity analyses (predefined outlier rules, multiplicity adjustments), and archive certified assay validation summaries in the TMF. Update the Investigator’s Brochure with Phase II findings, including dose/schedule rationale and any age-based stratified recommendations. The Phase III protocol should carry forward: (1) the selected regimen(s); (2) primary endpoints (clinical efficacy and/or immunobridging depending on pathogen context); (3) event-driven or fixed-sample design assumptions; and (4) a risk-based monitoring plan calibrated to Phase II signals. Ensure that operational SOPs (randomization, unblinding, sample handling, deviation management) are referenced to current, controlled versions, and that every decision in Phase II is traceable via meeting minutes, DSMB recommendations, and SAP-anchored outputs. With these pieces in place, your study is not only scientifically justified but also inspection-ready for regulators and sponsors.

]]>